Nectin-4 is frequently expressed in primary salivary gland cancer and corresponding lymph node metastases and represents an important treatment-related biomarker

Many locally advanced and metastatic salivary gland carcinomas (SGC) lack therapeutic targets. Enfortumab vedotin, an antibody–drug conjugate binding to Nectin-4, recently gained FDA approval for third-line urothelial carcinoma. Therefore, the aim of this study was to assess the expression of Nectin...

Descripción completa

Detalles Bibliográficos
Autores principales: Mayer, Marcel, Nachtsheim, Lisa, Prinz, Johanna, Shabli, Sami, Suchan, Malte, Klußmann, Jens Peter, Quaas, Alexander, Arolt, Christoph, Wolber, Philipp
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2023
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495532/
https://www.ncbi.nlm.nih.gov/pubmed/37480387
http://dx.doi.org/10.1007/s10585-023-10222-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495532/
https://www.ncbi.nlm.nih.gov/pubmed/37480387
http://dx.doi.org/10.1007/s10585-023-10222-w

Ejemplares similares